Nelson Hospital, Nelson, New Zealand.
Emerg Med Australas. 2022 Oct;34(5):818-821. doi: 10.1111/1742-6723.14006. Epub 2022 May 14.
Headache is a common presenting complaint to the ED. Using time from the first provider to discharge as a surrogate for effectiveness, we aimed to determine if intranasal (IN) droperidol is as beneficial as usual treatment for acute headache in the ED.
There were 1213 consecutive presentations of adults with acute headache over a 42-month period. Electronic records for each event were interrogated, 406 events met pre-determined exclusion criteria. Of the remaining 805 eligible patient events, 139 received IN droperidol, whereas 666 were given usual therapy.
There was a 20 min reduction of mean and median ED length of stay (LOS) for the group that got treated with IN droperidol.
IN droperidol reduced LOS in the ED. There are potential cost savings of this effective treatment via this novel route. A prospective multi-centre study of the use of IN droperidol for the treatment of acute headache in the ED is recommended.
头痛是急诊科常见的就诊主诉。我们旨在通过从首诊医生到出院的时间作为替代指标来评估经鼻给予氟哌利多是否与急诊科急性头痛的常规治疗一样有效。
在 42 个月的时间里，共有 1213 例成人急性头痛就诊。对每个事件的电子记录进行了查询，406 个事件符合预先确定的排除标准。在剩余的 805 例合格的患者事件中，139 例接受了经鼻给予氟哌利多，而 666 例给予了常规治疗。
接受经鼻给予氟哌利多治疗的患者的平均和中位数急诊科住院时间（ LOS ）分别减少了 20 分钟。
经鼻给予氟哌利多可缩短急诊科 LOS 。通过这种新途径，这种有效治疗可能会节省成本。建议开展一项多中心前瞻性研究，评估经鼻给予氟哌利多治疗急诊科急性头痛的效果。
